Gabrielle Silver
CEO
Gabrielle joined as the CEO of Bioscript Group in 2022 with a passion for accelerating innovation across life sciences. She is a physician by background and moved into the pharmaceutical sector, from clinical practice, more than 20 years ago.
She has led both medical affairs and commercial teams at a global level specialising in neurology and psychiatry. Her career has also focused on the role of technology and companion diagnostics in delivering better patient outcomes. She led global marketing programmes for Alzheimer’s disease diagnostics as well as developing machine data software solutions in the field of anaesthesia.
Gaby has worked agency side as a Partner in corporate and financial communications across life sciences.
Her board level roles have focused on health and social care services businesses, the NHS and US speciality pharma, working on therapeutics in addiction.
Gaby’s role at Bioscript Group is to ensure that the teams bring the best of Bioscript scientific, regulatory and market access capability to our clients. In recognising the complexity of the development, approval and commercialisation ecosystem, she is committed to building long term strategic partnerships to allow innovative therapeutics to reach patients as quickly as possible.
